Chahinian P A, Arnold D J, Cohen J M, Purpora D P, Jaffrey I S, Teirstein A S, Kirschner P A, Holland J F
JAMA. 1977 May 30;237(22):2392-6.
A combination chemotherapy (MACC) consisting of methotrexate, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and lomustine (CCNU) was given to 41 patients with stage III bronchogenic carcinoma, 34 of whom had disseminated disease. The objective response rate was 46% for all patients with a median actuarial survival of nine months. Response was seen in all cell types, including four of ten patients with squamous cell carcinoma, six of 17 with adenocarcinoma, and six of seven with small-cell anaplastic carcinoma. Prolongation of survival was apparent for patients of all cell types. Toxic reactions were moderate and allowed for easy outpatient use.
对41例Ⅲ期支气管癌患者给予了由甲氨蝶呤、盐酸阿霉素（阿霉素）、环磷酰胺和洛莫司汀（环己亚硝脲）组成的联合化疗方案（MACC），其中34例有播散性病变。所有患者的客观缓解率为46%，中位精算生存期为9个月。所有细胞类型均可见缓解，包括10例鳞状细胞癌患者中的4例、17例腺癌患者中的6例以及7例小细胞间变性癌患者中的6例。所有细胞类型的患者生存期均有延长。毒性反应较轻，便于门诊使用。
